Overall Fundamental outlook

Business Operations:

Sector: Basic Materials
Industry: Specialty Chemicals

Jubilant Ingrevia Limited engages in the life science products and solutions in India, the United States, Europe, China and internationally. It operates in three segments: Specialty Chemicals, Nutrition & Health Solutions, and Chemical Intermediates. The Specialty Chemicals segment offers bio-pyridine and -picolines, fine chemicals, agro chemicals, custom development and manufacturing services, and microbial control solutions. The Nutrition & Health Solutions segment provides nutrition and health ingredients; and animal and human nutrition health solutions. The Chemical intermediates segment offers acetyls and specialty ethanol. The company provides piperidines, metal complexes, choline salts, vitamin B3, Vitamin B4, picolinates, riboflavin phosphate sodium, nutritional premixes, antioxidants, straight ingredients, acetic anhydride, acetic acid, ethyl acetate, propionic anhydride, formaldehyde, bio acetic acid-food grade, acetaldehyde, and ethanol, as well as cyano, acetyl, amino, halo, alkyl, and aldehyde pyridines. In addition, it offers route design, process development, process optimization, and scale-up and commercial manufacturing of intermediates. Further, the company provides vitamins, mineral premixes, stress regulator, amino acid, herbal choline, herbal non-antibiotic growth promoter and egg quality enhancer, toxin binder, acidifiers, and enzymes and emulsifiers. It serves pharmaceutical, animal and human nutrition, agrochemical, personal and consumer care, and industrial customers. The company was formerly known as Jubilant LSI Limited and changed its name to Jubilant Ingrevia Limited in October 2020. Jubilant Ingrevia Limited was incorporated in 2019 and is headquartered in Noida, India.

Revenue projections:

Revenue projections for JUBLINGREA
Revenue projections for JUBLINGREA

Investors may react cautiously to news that JUBLINGREA's revenues are forecasted to be lower than last year's. Such declines are likely to have a negative effect on the company's bottom line, which can lead to concerns about profitability and hinder investor confidence in the company's future performance.

Financial Ratios:

currentRatio 1.34600
forwardPE 25.37234
debtToEquity 26.51000
earningsGrowth 0.18000
revenueGrowth 0.07200
grossMargins 0.47602
operatingMargins 0.08413
trailingEps 18.20000
forwardEps 25.16914

JUBLINGREA's current ratio is 1.346, showing the company's capacity to service its short-term debt through its cash reserves and current assets. This is a positive indicator of liquidity, suggesting JUBLINGREA has no trouble covering its short-term financial obligations.
JUBLINGREA's Forward PE is in a favorable range, suggesting the stock is reasonably priced relative to its earnings. This indicates the stock is not overpriced, providing room for potential growth and making it an attractive option for investors looking for solid value and future upside.
JUBLINGREA's low Debt-to-Equity ratio means the company is not highly leveraged. This suggests a sound financial position with minimal reliance on debt, reducing risk and ensuring greater financial flexibility, making it a more stable option for investors.
JUBLINGREA's forward EPS exceeds its trailing EPS, indicating that the company is projected to be more profitable in the current financial year compared to the previous one. This suggests positive growth and improved earnings, signaling an optimistic outlook for JUBLINGREA's financial performance.

Price projections:

Price projections for JUBLINGREA
Price projections for JUBLINGREA

JUBLINGREA's price has consistently hovered near the lower end of price projections. This trend suggests that the stock is underperforming relative to analyst expectations, indicating a potential lack of momentum for upward movement in the near future.

Insider Transactions:

Insider Transactions for JUBLINGREA
Insider Transactions for JUBLINGREA


JUBLINGREA experienced 2 selling transactions, with market price of 686.4500122070312.JUBLINGREA had 9 buy transactions while market price was at 721.272230360243 per share.More sells than buys at JUBLINGREA's current price levels suggest potential weakness. If this trend continues, the stock may experience further price declines as selling pressure increases.

Recommendation changes over time:

Recommendations trend for JUBLINGREA
Recommendations trend for JUBLINGREA


Analysts' buy bias toward Jubilant Ingrevia Limited suggests the stock is seen as a solid investment, potentially motivating investors to consider it for their portfolios. With this positive outlook, Jubilant Ingrevia Limited is likely to be viewed as a secure place to allocate funds, driving further interest in the stock.